FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.815,92 -570,17 (-1,49%) Nasdaq
15.657,82 -325,26 (-2,04%) Nikkei 225
38.229,79 -175,87 (-0,46%) Petrolio
81,20 -0,73 (-0,89%) Bitcoin EUR
56.413,55 -3.557,79 (-5,93%)
ALK-Abelló A/S (0OIR.IL)
| Chiusura precedente | 149,45 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 47.060 |
| Capitalizzazione | 30,001B |
| Beta (5 anni mensile) | 0,31 |
| Rapporto PE (ttm) | 92,83 |
| EPS (ttm) | 1,61 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 16 mar 2017 |
| Stima target 1A | N/D |
GlobeNewswireLarge Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
The Phase 3 efficacy and safety trial of ALK’s tree tablet involved 952 children aged 5 to 17 in Canada and Europe.ALK has now successfully completed pivotal clinical development for all five respiratory allergy immunotherapy tablets across all relevant age groups. ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced top-line results from a Phase 3 paediatric clinical trial of its sublingual allergy immunotherapy tablet for the treatment of tree-pollen-induced allergic rhinoconjunctivitis. The tre
- GlobeNewswire
Six-month interim report (Q2) 2023
ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and double-digit growth in combined SCIT/SLIT-drops sales. Operating profit (EBIT) increased by 120% in local currencies on sales growth and gross margin improvements. Q2 2023 financial highlights Comparative figures for Q2 2022 are shown in brackets. Revenue growth rates are stated in local currencies, unless otherwise indicated Revenue incre
- GlobeNewswire
Release date of six-month interim report (Q2) 2023 for ALK and audio cast
On Thursday, 24 August 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its six-month interim report (Q2) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CEST) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins. Participants in the conference call are kindly reques
